These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9248659)

  • 1. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
    Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
    Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
    Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
    J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short and long-term effects of interferon on serum markers of hepatitis C virus replication.
    Yatsuhashi H; Inoue O; Inokuchi K; Koga M; Nagataki S; Cha TA; Irvine B; Stempien M; Kolberg J; Urdea MS
    J Gastroenterol Hepatol; 1993; 8(1):1-6. PubMed ID: 8382537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C long-term responders to human leukocyte interferon-alpha therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance.
    Morisco F; Tuccillo C; Iasevoli P; Sessa G; Brunasso G; Caporaso N
    Eur J Gastroenterol Hepatol; 1998 May; 10(5):399-403. PubMed ID: 9619386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    J Med Virol; 1997 Apr; 51(4):313-8. PubMed ID: 9093946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders.
    Yoshioka K; Aiyama T; Iwata K; Yano M; Okumura A; Ishikawa T; Kakumu S
    Am J Gastroenterol; 1997 Aug; 92(8):1305-9. PubMed ID: 9260795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia.
    Bonetti P; Chemello L; Antona C; Breda A; Brosolo P; Casarin P; Crivellàro C; Donà G; Martinelli S; Rinaldi R; Zennaro V; Santonastaso M; Urban F; Pontisso P; Alberti A
    J Viral Hepat; 1997 Mar; 4(2):107-12. PubMed ID: 9097266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of serum hepatitis C virus levels in patients with chronic hepatitis C treated with two courses of interferon administration.
    Saitoh Y; Miura M; Niitsuma H; Numata N; Ohori H; Ishii M; Toyota T
    Tohoku J Exp Med; 1994 Aug; 173(4):361-9. PubMed ID: 7529950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon.
    Frangeul L; Cresta P; Perrin M; Duverlie G; Khorsi H; Musset L; Opolon P; Huraux JM; Lunel F
    J Hepatol; 1998 Apr; 28(4):538-43. PubMed ID: 9566820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.
    Kakumu S; Yoshika K; Tanaka K; Higashi Y; Kurokawa S; Hirofuji H; Kusakabe A
    J Med Virol; 1993 Sep; 41(1):65-70. PubMed ID: 8228941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
    Fargion S; Fracanzani AL; Sampietro M; Molteni V; Boldorini R; Mattioli M; Cesana B; Lunghi G; Piperno A; Valsecchi C; Fiorelli G
    Eur J Gastroenterol Hepatol; 1997 May; 9(5):497-503. PubMed ID: 9187884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.